The current study suggests that elevated AFP, larger tumor size, stage 3 disease, low facility case volume, increased time interval from diagnosis to receiving SBRT, and low BED are associated with poor survival for unresectable HCC patients treated with SBRT. Here, AFP is linked to hepatocellular carcinoma.